<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446715</url>
  </required_header>
  <id_info>
    <org_study_id>17062020</org_study_id>
    <nct_id>NCT04446715</nct_id>
  </id_info>
  <brief_title>Comparison of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Cesarean Section</brief_title>
  <official_title>Comparison of Clinical Effects of Meperidine and Sufentanil Added to 0.5% Hyperbaric Bupivacaine for Spinal Anesthesia in Patients Undergoing Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makassed General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makassed General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subarachnoid block is a widely used anesthetic technique for cesarean section. To improve the&#xD;
      quality of analgesia and prolong its duration, the addition of intrathecal opioids to local&#xD;
      anesthetics has been encouraged.&#xD;
&#xD;
      In a double blind randomized controlled trial, 60 parturient women ASA 2-3 scheduled for&#xD;
      elective cesarean delivery under spinal anesthesia will be randomly divided into 2 groups:&#xD;
      Group 1 will receive sufentanil 5 μg and Group 2 will receive meperidine 12.5 mg. In every&#xD;
      group, 0.5% heavy bupivacaine 10 will be added.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A questionnaire will be used to collect data. Patients' demographic and operative&#xD;
      characteristics will be recorded. These include block level, heart rate, mean arterial&#xD;
      pressure, nausea, vomiting, shivering and use of vasopressors. Post-operative data include&#xD;
      pain, analgesic consumption, nausea and vomiting, as well as patients and surgeons&#xD;
      satisfaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First analgesic request time</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>The duration of effective analgesia is defined as the time from intrathecal injection to first patient analgesic demand</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirements</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>A questionnaire will be used to record the analgesics consumed by the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Sufentanil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meperidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>Patients will receive sufentanil in spinal anesthesia</description>
    <arm_group_label>Sufentanil Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meperidine</intervention_name>
    <description>Patients will receive meperidine in spinal anesthesia</description>
    <arm_group_label>Meperidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Patients will receive 0.5% heavy bupivacaine in spinal anesthesia</description>
    <arm_group_label>Meperidine Group</arm_group_label>
    <arm_group_label>Sufentanil Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women with American Society of Anesthesiologist (ASA) 2-3&#xD;
&#xD;
          -  scheduled for elective cesarean section.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refuse to participate in the study,&#xD;
&#xD;
          -  requiring emergency obstetric care,&#xD;
&#xD;
          -  ASA IV or V,&#xD;
&#xD;
          -  having systemic diseases,&#xD;
&#xD;
          -  a known fetal anomaly,&#xD;
&#xD;
          -  placenta previa,&#xD;
&#xD;
          -  abruption placenta&#xD;
&#xD;
          -  with a history of hypersensitivity or allergy to any of the study drugs,&#xD;
&#xD;
          -  operation time longer than 1.5 hour,&#xD;
&#xD;
          -  blood loss more than 1500 millilitres,&#xD;
&#xD;
          -  those with any contraindication to the technique proposed,&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saleh Kanawati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makassed General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saleh Kanawati, MD</last_name>
    <phone>+9611636000</phone>
    <phone_ext>6405</phone_ext>
    <email>s.kanawati@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makassed General Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saleh Kanawati, MD</last_name>
      <phone>+9611636000</phone>
      <phone_ext>6405</phone_ext>
      <email>s.kanawati@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makassed General Hospital</investigator_affiliation>
    <investigator_full_name>Saleh Kanawati</investigator_full_name>
    <investigator_title>Acting chairperson</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

